Effects of calcium channel blockers on cloned cardiac K+ channels I(Kr) and I(Ks)

Therapie

Volumn 55, Issue 1, 2000, Pages 195-202

  Chouabe, C ^a   Drici, M D ^a   Romey, G ^a   Barhanin, J ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Arrhythmia; Long QT syndrome; Torsade de pointes

Indexed keywords

BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; MIBEFRADIL; NITRENDIPINE; POTASSIUM CHANNEL; VERAPAMIL;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CATION TRANSPORT PROTEINS; CLONING, MOLECULAR; COS CELLS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; KCNQ POTASSIUM CHANNELS; KCNQ1 POTASSIUM CHANNEL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 0034067415     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Hosey MM, Lazdunski M. Calcium channels: molecular pharmacology, structure and regulation. J Membr Biol 1988; 104: 81-105.
2. Clozel JP, Ertel EA, Ertel SI. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens 1997; 15: S17-S25.
3. Roden DM. Antiarrhythmic drugs. In: Goodman and Gilman, eds. Antiarrhythmic Drugs, Ninth edn. New York: McGraw-Hill, 1996; 839-874.
4. Campbell RM, Woosley RL, Iansmith DHS et al. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. PACE 1990; 13: 30-36.
5. Lauer MR, Liem LB, Young C et al. Cellular and clinical electrophysiology of verapamil-sensitive ventricular tachycardias. J Cardiovasc Electrophysiol 1992; 3: 500-514.
6. Gill JS. Blaszyk K, Ward DE et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 1993; 126: 1126-1133.
7. Lee KL, Lauer MR, Young C et al. Spectrum of electrophysiologic and electropharmacologic characteristics of verapamil-sensitive ventricular tachycardia in patients without structural heart disease. Am J Cardiol 1996; 77: 967-973.
8. + current-differential sensitivity to block by Class-III antiarrhythmic agents. J Gen Physiol 1990; 96: 195-215.
9. + current in human ventricular myocytes. Circ Res 1996; 78: 689-696.
10. Manouvrier J, Sagot M, Carson C et al. Nine cases of torsades de pointes with bepridil administration. Am Heart J 1986; 5: 1005-1007.
11. Napolitano C, Priori S, Schwartz P. Torsade de pointes. Mechanism and management. Drugs 1994; 47: 51-65.
12. + channels. J Pharmacol Exp Ther 1985; 234: 134-140.
13. Kr potassium channel. Cell 1995; 81: 299-307.
14. Ks cardiac potassium current. Nature 1996; 384: 78-80.
15. Ks potassium channel. Nature 1996; 384: 80-83.
16. Priori SG, Barhanin J, Hauer RN et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III [in process citation]. Circulation 1999; 99: 674-681.
17. Prioir SG, Barhanin J, Hauer RN et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II [in process citation]. Circulation 1999; 99: 518-528.
18. + channel mutations in Romano-Ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias. EMBO J 1997; 16: 5472-5479.
19. Snyders DJ, Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996; 49: 949-955.
20. Jurman ME, Boland LM, Yellen G. Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. BioTechniques 1994; 17: 876-881.
21. Hamill OP, Marty A, Neher E et al. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membranes patches. Eur J Physiol 1981; 391: 85-100.
22. + current in small-cell lung cancer cells. J Pharmacol Exp Ther 1991; 257: 184-191.
23. + channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 1995; 106: 745-779.
24. + channel cloned from human heart. Mol Pharmacol 1993; 44: 642-648.
25. Rauer H, Grissmer S. Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3. Mol Pharmacol 1996; 50: 1625-1634.
26. Loussouarn G, Charpentier F, Mohammed-Panah R et al. KvLQT1 potassium channel but not IsK is the molecular target for trans-6-Cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane. Mol Pharmacol 1997; 52: 1131-1136.
27. Balser JR, Bennett PB, Hondeghem LM et al. Suppression of time-dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 1991; 69: 519-529.
28. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997; 15: 137-156.
29. Massie BM. Mibefradil: a selective T-type calcium antagonist. Am J Cardiol 1997; 80: 231-321.
30. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 1986; 237: 9-17.
31. CAST. Preliminary report: effect of encainimide and flecanide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
32. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989; 63: 867-869.
33. Cosio FG, Goicolea A, Lopez GM et al. Suppression of torsades de pointes with verapamil in patients with atrioventricular block. Eur Heart J 1991; 12: 635-638.
34. DAVIT. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990; 66: 779-785.